eligibility_summary
Eligibility: ≥70 unfit/frail, untreated, histologically confirmed DLBCL with measurable lesion ≥15 mm, life expectancy >3 mo, adequate organ function (EF ≥50%, AST/ALT ≤3×ULN, CrCl ≥30 mL/min, SpO2 >90% on room air), marrow reserve (Hgb ≥8, Plt ≥75 [≥50 if BM invasion], ANC ≥1.0 [≥0.75 if BM invasion]), consent, contraception if applicable. Exclude: severe hepatic/renal dysfunction, NYHA ≥2 heart disease/arrhythmia, uncontrolled infection, other active cancers, CNS DLBCL, systemic steroids, thromboembolism, psych barriers, likely noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions and mechanisms: Pomalidomide—oral immunomodulatory drug (IMiD), binds cereblon to degrade IKZF1/3, boosting T/NK-cell cytotoxicity, reducing pro-tumor cytokines and angiogenesis. Rituximab—anti-CD20 chimeric monoclonal antibody, depletes B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis. Orelabrutinib—covalent, highly selective BTK inhibitor, blocks B-cell receptor (BCR) signaling, dampening NF-κB/PI3K-AKT survival pathways. Polatuzumab vedotin—anti-CD79b antibody–drug conjugate (ADC) delivering MMAE, internalization releases microtubule inhibitor causing G2/M arrest and apoptosis. Targets/pathways: malignant CD20+/CD79b+ B cells, BCR-BTK signaling and downstream NF-κB/AKT, microtubules (via MMAE), immune effector activation and Fc-mediated ADCC/CDC.